COVID-19 clinical trials summary (data from ClinicalTrials.gov, 7 May 2020), n=1221
Study characteristic | No of studies |
Study type | |
Patient registry | 84 |
Observational | 485 |
Interventional | 736 |
Early phase I | 15 |
Phase I | 66 |
Phase II | 290 |
Phase III | 200 |
Phase IV | 47 |
Funding | |
US Federal Government | 3 |
NIH* | 11 |
Industry | 138 |
Other† | 585 |
Location (study site)‡ | |
Europe | 459 |
North America | 294 |
East Asia | 87 |
Middle East | 55 |
Africa | 36 |
South America | 34 |
South Asia | 16 |
Southeast Asia | 11 |
North Asia | 6 |
Pacifica | 6 |
Central America | 2 |
*US National Institutes of Health.
†Individuals, universities, organisations.
‡Some studies have more than one study site within and across countries.